Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer
Mika Tirkkonen(Tampere University Hospital), �ke Borg, Tommi Kainu(National Human Genome Research Institute), Håkan Olsson(Nokia (Finland)), R�sa B. Barkard�ttir, Niklas Loman(Lund University), �skar T. J�hannsson(Lund University), Olli Kallioniemi(University of Helsinki)
Genes Chromosomes and Cancer
January 1, 1999
Cited by 66
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
|Cancer Cell|2017|534